Disease-specific tau polymorphs define unique protein interaction networks across proteinopathies
Nicha PuangmalaiiD, Nemil N. BhattiD, Nopparat Suthprasertporn, Ernesto G. Miranda-MoralesiD, Nikita Shchankin, Madison Samples, Ahmet E. Balci, Jia Yi LiewiD, Mauro MontalbanoiD, Yingxin ZhaoiD, Rakez KayediD
Abstract
Tau protein aggregates exhibit distinct conformations across tauopathies, but their disease-specific protein interactions remain poorly understood. Here, we demonstrate that disease-specific tau conformations determine unique protein interaction landscapes across Alzheimers disease (AD), progressive supranuclear palsy (PSP), and dementia with Lewy bodies (DLB). Through comprehensive interactome profiling of misfolded tau aggregates from PBS- and sarkosyl-soluble fractions. We identified 493 high-confidence proteins with remarkable disease specificity--notably, no common interactors overlapping across all three tauopathies. Machine learning classification achieved compelling discrimination between diseases using as few as 4-6 proteins features, demonstrating robust molecular signatures underlying clinical heterogeneity. AD derived tau aggregates uniquely engaged cellular metabolism machinery, including key glycolytic enzymes and TCA cycle proteins, alongside glutamate/GABA neurotransmitter cycling components, with the astrocytic glutamate transporter SLC1A2 showing 27-fold enrichment over other tauopathies. In contrast, PSP tau displayed the most distinctive profile, with extensive protein depletion (52/57 significant proteins) and selective enrichment of proteasome components, particularly PSMB7 showing >3000-fold abundance. DLB tau is associated with neurogenesis modulators while depleting neuroinflammatory mediators. These interaction patterns were validated through proximity ligation assays and correlated with distinct post-translational modification profiles, with PSP tau exhibiting globally elevated ubiquitination, AD showing mixed modification patterns, and DLB displaying minimal ubiquitination. Critically, sarkosyl-soluble fractions revealed reduced interactome complexity across diseases, except for PSP tau which maintained robust interactions with GPCR-ERK signaling and kinetochore proteins, suggesting unique aggregation mechanisms. Our findings establish that conformationally distinct tau strains dictate disease-specific protein interaction networks, providing molecular insight into tauopathy diversity and identifying novel therapeutic targets for precision medicine approaches in neurodegeneration.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Small tau aggregates exhibit disease-specific molecular profiles across tauopathies
Dorothea Böken, Melissa Huang, … David Klenerman·Cell ReportsPeer-reviewed·Feb 1, 2026
- Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies
Dmytro Morderer, Melissa C. Wren, … Wilfried Rossoll·Molecular NeurodegenerationPeer-reviewed·Mar 13, 2025
- Proximity labeling of the Tau repeat domain enriches RNA-binding proteins that are altered in Alzheimer's disease and related tauopathies
Sarah M. Shapley, Anantharaman Shantaraman, … Nicholas T. Seyfried·Molecular & Cellular ProteomicsPeer-reviewed·Nov 7, 2025
- Novel Tau Interaction Partners as Potential Biomarkers and Therapeutic Targets in Neurodegenerative Diseases
Karoline Pichlerová, Jakub Šinský, … Jozef Hanes·bioRxiv·Nov 9, 2026
- Progressive Remodeling of Global Protein Interaction Networks in a Mouse Model of Tauopathy
Weiwei Lin, Sadhna Phanse, … Benjamin L. Wolozin·Cell ReportsPeer-reviewed·Oct 1, 2026
- Role of molecular polymorphism in defining tau filament structures in neurodegenerative diseases
X. Xiang, T. Arakhamia, … A. Fitzpatrick·bioRxiv·May 24, 2021